T1	Participants 386 449	patients who underwent percutaneous coronary intervention (PCI)
T2	Participants 494 612	patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial
T3	Participants 614 672	Patients were randomly assigned to placebo or eptifibatide
T4	Participants 924 953	Patients with CrCl <60 ml/min
